Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) posted its quarterly earnings data on Thursday. The company reported $0.23 EPS for the quarter, beating analysts' consensus estimates of ($0.37) by $0.60, Zacks reports. The company had revenue of $14.00 million for the quarter, compared to analyst estimates of $43.73 million.
Monte Rosa Therapeutics Stock Performance
NASDAQ:GLUE traded up $0.03 during trading hours on Monday, hitting $5.83. 843,088 shares of the company's stock traded hands, compared to its average volume of 938,441. The stock's fifty day moving average price is $6.18 and its two-hundred day moving average price is $6.78. The firm has a market cap of $358.18 million, a P/E ratio of -3.19 and a beta of 1.50. Monte Rosa Therapeutics has a twelve month low of $3.21 and a twelve month high of $12.40.
Wall Street Analysts Forecast Growth
GLUE has been the subject of a number of research analyst reports. Wells Fargo & Company cut their price target on shares of Monte Rosa Therapeutics from $11.00 to $10.00 and set an "equal weight" rating for the company in a report on Friday. Wedbush reaffirmed an "outperform" rating and set a $17.00 price objective (up from $15.00) on shares of Monte Rosa Therapeutics in a research note on Thursday. Finally, Lifesci Capital began coverage on shares of Monte Rosa Therapeutics in a report on Wednesday, March 12th. They issued an "outperform" rating and a $19.00 target price for the company.
Get Our Latest Report on GLUE
About Monte Rosa Therapeutics
(
Get Free Report)
Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.
Featured Articles
Before you consider Monte Rosa Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monte Rosa Therapeutics wasn't on the list.
While Monte Rosa Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
